Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer

M. Lopez, P. Vici, L. Di Lauro, G. Paoletti, T. Gionfra, F. Conti, S. Carpano, F. Pignatti, D. Giannarelli

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The aim of this study was to determine if lonidamine (LND) supplementation to single-agent epirubicin (EPI) could reverse anthracycline resistance in patients with metastatic breast cancer. 45 patients with metastatic breast cancer were treated with EPI 120 mg/m2 by intravenous (i.v.) bolus every 3 weeks. Patients who progressed were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2 and 450 mg on days 3-5. Among the 40 evaluable patients, 6 complete responses (CR) and 14 partial responses (PR) were achieved with EPI treatment alone for an overall response rate of 50%. The median duration of response was 6.5 months. Among the 25 patients treated with EPI+LND, 5 PR (21% of 24 evaluable patients) were observed with a median duration of response of 7 months. The median survival in patients receiving both treatments was 20 months. The survival for all patients was 18 months. The survival of patients receiving LND was not significantly longer than for the other patients. Myelotoxicity was the most common side-effect followed by alopecia, nausea and vomiting, and stomatitis. LND-related toxic effects were mild-to-moderate epigastralgia and myalgia. Anthracycline-related toxicity was the same in the two treatment groups. This study indicates that LND may circumvent clinical resistance to EPI without altering the pattern or severity of the toxicity of this anthracycline. Continued investigation of the clinical modulation of EPI resistance by LND in breast cancer is warranted, hopefully in patients with known multidrug resistance status.

Original languageEnglish
Pages (from-to)1611-1614
Number of pages4
JournalEuropean Journal of Cancer
Volume31
Issue number10
DOIs
Publication statusPublished - 1995

Fingerprint

Epirubicin
Breast Neoplasms
Anthracyclines
Survival
lonidamine
Stomatitis
Poisons
Myalgia
Alopecia
Multiple Drug Resistance
Nausea
Vomiting
Therapeutics

Keywords

  • breast cancer
  • chemotherapy
  • epirubicin
  • lonidamine
  • multidrug resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. / Lopez, M.; Vici, P.; Di Lauro, L.; Paoletti, G.; Gionfra, T.; Conti, F.; Carpano, S.; Pignatti, F.; Giannarelli, D.

In: European Journal of Cancer, Vol. 31, No. 10, 1995, p. 1611-1614.

Research output: Contribution to journalArticle

Lopez, M. ; Vici, P. ; Di Lauro, L. ; Paoletti, G. ; Gionfra, T. ; Conti, F. ; Carpano, S. ; Pignatti, F. ; Giannarelli, D. / Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. In: European Journal of Cancer. 1995 ; Vol. 31, No. 10. pp. 1611-1614.
@article{60c9c9c0d242425395d5d8fa70d26b4b,
title = "Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer",
abstract = "The aim of this study was to determine if lonidamine (LND) supplementation to single-agent epirubicin (EPI) could reverse anthracycline resistance in patients with metastatic breast cancer. 45 patients with metastatic breast cancer were treated with EPI 120 mg/m2 by intravenous (i.v.) bolus every 3 weeks. Patients who progressed were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2 and 450 mg on days 3-5. Among the 40 evaluable patients, 6 complete responses (CR) and 14 partial responses (PR) were achieved with EPI treatment alone for an overall response rate of 50{\%}. The median duration of response was 6.5 months. Among the 25 patients treated with EPI+LND, 5 PR (21{\%} of 24 evaluable patients) were observed with a median duration of response of 7 months. The median survival in patients receiving both treatments was 20 months. The survival for all patients was 18 months. The survival of patients receiving LND was not significantly longer than for the other patients. Myelotoxicity was the most common side-effect followed by alopecia, nausea and vomiting, and stomatitis. LND-related toxic effects were mild-to-moderate epigastralgia and myalgia. Anthracycline-related toxicity was the same in the two treatment groups. This study indicates that LND may circumvent clinical resistance to EPI without altering the pattern or severity of the toxicity of this anthracycline. Continued investigation of the clinical modulation of EPI resistance by LND in breast cancer is warranted, hopefully in patients with known multidrug resistance status.",
keywords = "breast cancer, chemotherapy, epirubicin, lonidamine, multidrug resistance",
author = "M. Lopez and P. Vici and {Di Lauro}, L. and G. Paoletti and T. Gionfra and F. Conti and S. Carpano and F. Pignatti and D. Giannarelli",
year = "1995",
doi = "10.1016/0959-8049(95)00200-3",
language = "English",
volume = "31",
pages = "1611--1614",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer

AU - Lopez, M.

AU - Vici, P.

AU - Di Lauro, L.

AU - Paoletti, G.

AU - Gionfra, T.

AU - Conti, F.

AU - Carpano, S.

AU - Pignatti, F.

AU - Giannarelli, D.

PY - 1995

Y1 - 1995

N2 - The aim of this study was to determine if lonidamine (LND) supplementation to single-agent epirubicin (EPI) could reverse anthracycline resistance in patients with metastatic breast cancer. 45 patients with metastatic breast cancer were treated with EPI 120 mg/m2 by intravenous (i.v.) bolus every 3 weeks. Patients who progressed were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2 and 450 mg on days 3-5. Among the 40 evaluable patients, 6 complete responses (CR) and 14 partial responses (PR) were achieved with EPI treatment alone for an overall response rate of 50%. The median duration of response was 6.5 months. Among the 25 patients treated with EPI+LND, 5 PR (21% of 24 evaluable patients) were observed with a median duration of response of 7 months. The median survival in patients receiving both treatments was 20 months. The survival for all patients was 18 months. The survival of patients receiving LND was not significantly longer than for the other patients. Myelotoxicity was the most common side-effect followed by alopecia, nausea and vomiting, and stomatitis. LND-related toxic effects were mild-to-moderate epigastralgia and myalgia. Anthracycline-related toxicity was the same in the two treatment groups. This study indicates that LND may circumvent clinical resistance to EPI without altering the pattern or severity of the toxicity of this anthracycline. Continued investigation of the clinical modulation of EPI resistance by LND in breast cancer is warranted, hopefully in patients with known multidrug resistance status.

AB - The aim of this study was to determine if lonidamine (LND) supplementation to single-agent epirubicin (EPI) could reverse anthracycline resistance in patients with metastatic breast cancer. 45 patients with metastatic breast cancer were treated with EPI 120 mg/m2 by intravenous (i.v.) bolus every 3 weeks. Patients who progressed were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2 and 450 mg on days 3-5. Among the 40 evaluable patients, 6 complete responses (CR) and 14 partial responses (PR) were achieved with EPI treatment alone for an overall response rate of 50%. The median duration of response was 6.5 months. Among the 25 patients treated with EPI+LND, 5 PR (21% of 24 evaluable patients) were observed with a median duration of response of 7 months. The median survival in patients receiving both treatments was 20 months. The survival for all patients was 18 months. The survival of patients receiving LND was not significantly longer than for the other patients. Myelotoxicity was the most common side-effect followed by alopecia, nausea and vomiting, and stomatitis. LND-related toxic effects were mild-to-moderate epigastralgia and myalgia. Anthracycline-related toxicity was the same in the two treatment groups. This study indicates that LND may circumvent clinical resistance to EPI without altering the pattern or severity of the toxicity of this anthracycline. Continued investigation of the clinical modulation of EPI resistance by LND in breast cancer is warranted, hopefully in patients with known multidrug resistance status.

KW - breast cancer

KW - chemotherapy

KW - epirubicin

KW - lonidamine

KW - multidrug resistance

UR - http://www.scopus.com/inward/record.url?scp=0028866197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028866197&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(95)00200-3

DO - 10.1016/0959-8049(95)00200-3

M3 - Article

C2 - 7488410

AN - SCOPUS:0028866197

VL - 31

SP - 1611

EP - 1614

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -